Nav: Home

The American College of Chest Physicians updates guidelines on PAH

February 07, 2019

Glenview, Illinois - The American College of Chest Physicians® (CHEST) announced the publication of updates to the evidence-based guidelines on therapy for pulmonary arterial hypertension (PAH). PAH is a progressive disease that affects the small arteries in the lungs, which can lead to right-sided heart failure and death. There is no cure for PAH; there are several medications approved for the treatment of the disease. In the latest evidence-based guideline, Therapy for Pulmonary Arterial Hypertension in Adults: Update of the CHEST Guideline and Expert Panel Report, experts provide 78 evidence-based recommendations for appropriate use in treating patients with PAH.

"New recommendations and ungraded consensus-based statements were developed in this update based on new studies that were published since the 2014 guidelines. In addition, an evidence-based and consensus-driven treatment algorithm was created to guide the clinician through an organized approach to management," says CHEST Pulmonary Arterial Hypertension Guidelines Committee Co-Chair, Dr. Deborah Jo Levine.

As part of the guideline development process, the panel updated the systematic review on the same clinical questions and criteria. Based on the results of the systematic review, the panel developed two new recommendations about pharmacologic therapy for PAH:
    * For treatment-naive patients with PAH who are World Health Organization (WHO) functional class II and III, we suggest initial combination therapy with ambrisentan and tadalafil to improve six-minute walk distance (6MWD).

    * For stable or symptomatic patients with PAH on background therapy with ambrisentan, we suggest the addition of tadalafil to improve 6MWD.
The complete guideline article is free to view in the Online First section of the journal CHEST®.
-end-
About CHEST Guidelines

Guidelines include systematically developed, evidence-based and periodically updated recommendations for the prevention, diagnosis and management of medical conditions. These guidelines are intended to inform health-care providers, patients and policy makers in making informed clinical decisions.

About the American College of Chest Physicians®

CHEST is the global leader in the prevention, diagnosis and treatment of chest diseases. Its mission is to champion advanced clinical practice, education, communication and research in chest medicine. It serves as an essential connection to clinical knowledge and resources for its 19,000+ members from around the world who provide patient care in pulmonary, critical care and sleep medicine. For information about the American College of Chest Physicians and its flagship journal CHEST®, visit chestnet.org.

American College of Chest Physicians

Related Pulmonary Arterial Hypertension Articles:

Evidence review supports pediatric use of PDE-5 inhibitors for pulmonary hypertension
A systematic review of the comparative effectiveness and safety of phosphodiesterase type 5 inhibitors in pediatric patients with pulmonary hypertension published Feb.
Selexipag in pulmonary arterial hypertension: Added benefit not proven
The data in the dossier were unsuitable to show an added benefit: Comparator therapy and division of the population were inadequate.
YEARS algorithm in suspected pulmonary embolism: Towards a reduced rate of pulmonary imaging
Patients with suspected pulmonary embolism often undergo computed tomography pulmonary angiography to confirm or exclude the diagnosis.
New understanding of pulmonary hypertension leads to promising drug targets
A groundbreaking study from the University of Pittsburgh and UPMC identifies new compounds that could have robust effects in treating pulmonary hypertension.
New testing method developed for genetic mutation that causes pulmonary hypertension
Pulmonology and genetics experts from two Utah healthcare organizations have collaboratively developed a new diagnostic genomic testing method for a rare form of pulmonary hypertension caused by a genetic mutation they discovered three years ago.
Early echocardiography to study pulmonary hypertension in mouse model of bronchopulmonary dysplasia
Researchers at Baylor College of Medicine who focus on bronchopulmonary dysplasia and pulmonary hypertension, a common lung disease in premature infants, have shown that echocardiography can be used to detect the pulmonary hypertension in neonatal mice at an earlier time point than previously thought.
Protein target may block deadly arterial remodeling in pulmonary hypertension
Pulmonary hypertension is a highly lethal disease that transforms the thin, flexible vasculature of the lungs into thick, dysfunctional blood vessels that can kill.
Blood test shows promise in gauging severity of pulmonary arterial hypertension
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.
MicroRNA may help control arterial thrombosis
In a new study published online this week in The FASEB Journal, a Brigham and Women's Hospital research team investigated the role of miR-181b in blocking the development of arterial thrombosis.
Pulmonary artery stiffening is an early driver of pulmonary hypertension
In this issue of JCI Insight, a team led by Laura Fredenburgh of Brigham and Women's Hospital shows that alterations in pulmonary arterial stiffness occur early during disease and promote vascular remodeling by altering signaling mediated by prostaglandins, a class of hormones that regulate inflammation, smooth muscle contraction, and vasoconstrictoin.

Related Pulmonary Arterial Hypertension Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#529 Do You Really Want to Find Out Who's Your Daddy?
At least some of you by now have probably spit into a tube and mailed it off to find out who your closest relatives are, where you might be from, and what terrible diseases might await you. But what exactly did you find out? And what did you give away? In this live panel at Awesome Con we bring in science writer Tina Saey to talk about all her DNA testing, and bioethicist Debra Mathews, to determine whether Tina should have done it at all. Related links: What FamilyTreeDNA sharing genetic data with police means for you Crime solvers embraced...